Causal Assessment of Pharmaceutical Treatments: Why Standards of Evidence Should not be the Same for Benefits and Harms? Barbara OsimaniFiorenzo Mignini Current Opinion 18 December 2014 Pages: 1 - 11
The US Food and Drug Administration-European Medicines Agency Collaboration in Pharmacovigilance: Common Objectives and Common Challenges Gerald J. Dal PanPeter R. Arlett Current Opinion 25 December 2014 Pages: 13 - 15
Optimal Glycaemic Control in Elderly People with Type 2 Diabetes: What Does the Evidence Say? Supriya MathurNicola N. ZammittBrian M. Frier Leading Article 07 December 2014 Pages: 17 - 32
The Comparative Efficacy and Safety of the Angiotensin Receptor Blockers in the Management of Hypertension and Other Cardiovascular Diseases Hazel Mae A. AbrahamC. Michael WhiteWilliam B. White Review Article 22 November 2014 Pages: 33 - 54
Aristolochic Acid Nephropathy: Epidemiology, Clinical Presentation, and Treatment Randy L. LucianoMark A. Perazella Review Article 02 December 2014 Pages: 55 - 64
Safety Considerations with Pharmacological Treatment of Gestational Diabetes Mellitus David Simmons Review Article 27 December 2014 Pages: 65 - 78
Bacillus Calmette-Guérin (BCG) Vaccine Adverse Events in Victoria, Australia: Analysis of Reports to an Enhanced Passive Surveillance System Hazel J. ClothierLaine HoskingJim P. Buttery Original Research Article 05 December 2014 Pages: 79 - 86
Structured Assessment for Prospective Identification of Safety Signals in Electronic Medical Records: Evaluation in the Health Improvement Network S. CederholmG. HillG. N. Norén Original Research Article Open access 25 December 2014 Pages: 87 - 100
Comment on: “Desideratum for Evidence-Based Epidemiology” Sean HennessyCharles E. Leonard Letter to the Editor 16 December 2014 Pages: 101 - 103
Authors’ Reply to Hennessy and Leonard’s Comment on “Desideratum for Evidence-Based Epidemiology” J. Marc OverhagePatrick B. RyanPaul E. Stang Letter to the Editor 16 December 2014 Pages: 105 - 107
Comment on: “Adverse Drug Reaction Reporting by Patients: An Overview of Fifty Countries” Syed Rizwanuddin Ahmad Letter to the Editor 21 November 2014 Pages: 109 - 110
Authors’ Reply to Ahmad SR: “Adverse Drug Reaction Reporting by Patients: An Overview of Fifty Countries” Florence MargraffDelphine Bertram Letter to the Editor 21 November 2014 Pages: 111 - 111
Comment on: “Zoo or Savannah? Choice of Training Ground for Evidence-Based Pharmacovigilance” Rave HarpazWilliam DuMouchelNigam H. Shah Letter to the Editor 29 November 2014 Pages: 113 - 114
Authors’ Reply to Harpaz et al. Comment on: “Zoo or Savannah? Choice of Training Ground for Evidence-Based Pharmacovigilance” G. Niklas NorénOla CasterMarie Lindquist Letter to the Editor 29 November 2014 Pages: 115 - 116